ANAVEX LIFE SCIENCES CORP. Cash and Cash Equivalents
ANAVEX LIFE SCIENCES CORP. (AVXL) had Cash and Cash Equivalents of $118.33 million as of 2026-06-30, per its 10-Q filed 2026-08-28.
Financial Statements › Balance Sheet › Assets
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-28
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $118.33M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $127.42M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $131.75M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $102.58M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $118.33M 10-Q · filed 2026-08-28 | |
| 2026-03-31 | $127.42M 10-Q · filed 2026-08-28 | |
| 2025-12-31 | $131.75M 10-Q · filed 2026-02-09 | |
| 2025-09-30 | $102.58M 10-K/A · filed 2026-08-28 | |
| 2025-06-30 | $101.16M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $115.77M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $120.78M 10-Q · filed 2025-02-12 | |
| 2024-09-30 | $132.19M 10-K/A · filed 2026-08-28 | |
| 2024-06-30 | $138.76M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $139.39M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $143.76M 10-Q · filed 2024-02-07 | |
| 2023-09-30 | $151.02M 10-K · filed 2024-12-23 | |
| 2023-06-30 | $154.82M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $153.47M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $143.62M 10-Q · filed 2023-02-07 | |
| 2022-09-30 | $149.16M 10-K · filed 2023-11-27 | $149.16M 10-K · filed 2022-11-28 |
| 2022-06-30 | $153.20M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $153.34M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $151.15M 10-Q · filed 2022-02-09 | |
| 2021-09-30 | $152.11M 10-K · filed 2022-11-28 | |
| 2021-06-30 | $157.56M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $75.86M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $47.36M 10-Q · filed 2022-02-09 | |
| 2020-09-30 | $29.25M 10-Q · filed 2022-02-09 | |
| 2020-06-30 | $27.62M 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $26.56M 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $27.46M 10-Q · filed 2020-02-06 | |
| 2019-09-30 | $22.19M 10-Q · filed 2021-08-12 | |
| 2019-06-30 | $21.25M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $19.46M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $20.72M 10-Q · filed 2019-02-07 | |
| 2018-09-30 | $22.93M 10-K · filed 2019-12-16 | |
| 2018-06-30 | $25.83M 10-Q · filed 2019-08-07 | |
| 2018-03-31 | $25.66M 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $28.05M 10-Q · filed 2019-02-07 | |
| 2017-09-30 | $27.44M 10-K · filed 2019-01-25 | |
| 2017-06-30 | $24.79M 10-Q · filed 2018-08-09 | |
| 2017-03-31 | $23.35M 10-Q · filed 2018-05-10 | |
| 2016-09-30 | $9.19M 10-K · filed 2019-01-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |